Literature DB >> 7982059

Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC).

K Gohil1, J R Bell, J Ramachandran, G P Miljanich.   

Abstract

Neuronal voltage-sensitive calcium channels (VSCCs) are a diverse family of proteins that regulate entry of Ca2+ into neurons. Selective antagonists of VSCCs have proven to be powerful pharmacological tools for identifying and characterizing these channels. A new VSCC antagonist, SNX-230 (also known as omega-conopeptide MVIIC), binds with high affinity to receptors in rat brain and blocks one or more high-threshold VSCCs that are neither L- nor N-type. We have defined the neuroanatomical distribution of the high-affinity non-L, non-N VSCC receptors for SNX-230 using [125I]SNX-230 bound to rat brain sections and compared it with that of [125I]SNX-111, a reversible blocker of N-type VSCCs. Highest densities of binding for both ligands were seen in areas rich in synaptic connections, such as the oriens, radiatum and molecular layers of the hippocampus. In general, the density of [125I]SNX-230-binding was higher in cerebellum compared with that in forebrain. In contrast, this general distribution of density was reversed for [125I]SNX-111. In the glomeruli of the olfactory bulb, binding of [125I]SNX-230 was undetectable compared with the high density of [125I]SNX-111-binding. Differential localization of the two ligands was also seen in cervical spinal cord. The clearly different localization of [125I]SNX-230 compared with that of [125I]SNX-111 in the olfactory bulb and spinal cord suggested that the binding sites for [125I]SNX-230 in other brain regions, while co-localized macroscopically, are also distinct from those for [125I]SNX-111. This was confirmed when addition of saturating concentrations of SNX-111 did not affect the distribution pattern of [125I]SNX-230-binding.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7982059     DOI: 10.1016/0006-8993(94)90398-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  23 in total

Review 1.  Calcium channel functions in pain processing.

Authors:  John Park; Z David Luo
Journal:  Channels (Austin)       Date:  2010-11-01       Impact factor: 2.581

Review 2.  Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.

Authors:  Terrance P Snutch
Journal:  NeuroRx       Date:  2005-10

Review 3.  Drug development from marine natural products.

Authors:  Tadeusz F Molinski; Doralyn S Dalisay; Sarah L Lievens; Jonel P Saludes
Journal:  Nat Rev Drug Discov       Date:  2008-12-19       Impact factor: 84.694

Review 4.  Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.

Authors:  Mark Sanford
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

5.  Regulation of spinal substance p release by intrathecal calcium channel blockade.

Authors:  Toshifumi Takasusuki; Tony L Yaksh
Journal:  Anesthesiology       Date:  2011-07       Impact factor: 7.892

6.  Decreased calcium accumulation in isolated nerve endings during hibernation in ground squirrels.

Authors:  N T Gentile; M Spatz; M Brenner; R M McCarron; J M Hallenbeck
Journal:  Neurochem Res       Date:  1996-08       Impact factor: 3.996

Review 7.  Pharmacologic treatment of neuropathic pain.

Authors:  M S Wallace
Journal:  Curr Pain Headache Rep       Date:  2001-04

8.  Ziconotide.

Authors:  Katherine A Lyseng-Williamson; Caroline Perry
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 9.  Targeting voltage-gated calcium channels for neuropathic pain management.

Authors:  Danielle Perret; Z David Luo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain.

Authors:  Howard S Smith; Timothy R Deer
Journal:  Ther Clin Risk Manag       Date:  2009-07-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.